American Society of Hirudotherapy

Protocols for perioperative management of direct oral anticoagulants in hospitals: opportunities for improvement.

Research article published in Current medical research and opinion (2023)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsMitrovic et al. · Current medical research and opinion, 2023

Abstract

OBJECTIVES: To investigate and describe the protocolized perioperative management in patient using Direct oral anticoagulants (DOACs) in Dutch hospitals. METHODS: Between August and December 2020, a nationwide survey in 70 hospitals in the Netherlands was conducted. We asked hospital pharmacists to submit their protocols for perioperative management of DOAC (apixaban, dabigatran, edoxaban and rivaroxaban) users. The protocols were assessed for a number of parameters divided into categories: interruption and restart timetables DOACs for elective procedures, criteria for the start of an urgent procedure without antidotes, criteria for the use of antidotes and advised antidotes for urgent procedures. RESULTS: A total of 49 hospitals (70%) sent a protocol for perioperative management of DOACs. Two pairs of protocols were identical because hospitals cooperated closely, leaving 47 individual protocols for analysis. Thirty-five of these protocols contained a policy for both elective and urgent procedure; five protocols contained only a policy for elective and seven only for urgent procedures. In protocols for elective procedure, we found great variation in interruption and restart timetables intended for patients with renal impairment (Estimated Glomerular Filtration Ratio < 80 ml/min). In case of urgent procedures, there is variation in choice of antidote, criteria for administration of an antidote and antidote dosing. CONCLUSION: This study provides an overview of the current state of the perioperative protocols in the Netherlands in patients treated with direct oral anticoagulants. Protocols are often not complete and show important and unwanted variation. We have found that national guidelines do not provide unambiguous advice on all points (urgent procedures) and are therefore often elaborated at a local level. The results of this research can help in improving and harmonizing the perioperative protocols on a national level.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansAnticoagulantsHemorrhageAntidotesDabigatranRivaroxabanPyridonesAdministration, OralHospitalsAtrial Fibrillation

Summary

Protocols for perioperative management of direct oral anticoagulants in hospitals: opportunities for improvement.

Why This Matters for Hirudotherapy

This nationwide Dutch survey collected and analyzed 47 individual hospital protocols for perioperative management of direct oral anticoagulants (DOACs), finding that protocols were often incomplete and showed important, unwanted variation, particularly in interruption/restart timing for patients with renal impairment and in antidote choice and dosing for urgent procedures. Its bearing on hirudotherapy is indirect and contextual: it documents how much practical uncertainty still surrounds the perioperative use and reversal of even mainstream synthetic anticoagulants, the same clinical management problems that any antithrombotic agent, including leech-derived ones, must contend with around surgery. Honest caveat: this is a descriptive protocol survey of synthetic oral drugs in one country, with no clinical outcomes and no leech or hirudotherapy content whatsoever; it is background on the anticoagulation environment rather than evidence for leech therapy.

Citation

Protocols for perioperative management of direct oral anticoagulants in hospitals: opportunities for improvement.

Mitrovic et al. · Current medical research and opinion, 2023

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.